Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan To Establish iPS Medical Research Safety Guidelines

This article was originally published in PharmAsia News

Executive Summary

A research team at the Ministry of Health, Labor and Welfare is drafting guidelines addressing safety issues for using induced pluripotent stem cells in regenerative medicine. The guidelines will standardize issues related to generating and managing iPS cells for clinical studies; the purpose is to minimize adverse effects and carcinogenic risks. The Ministry aims to establish formal guidelines within 2010. It will be the world's first safety guidelines targeting iPS cells. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts